Medpace (MEDP) closed at $618.47 on Oct 16, 2026, down 1.6% on the day. The stock is up 0.5% over the past month, up 17.1% over three months, up 10.1% year to date and up 20.3% over the past year. It trades 8.8% below its 52-week high of $677.90 and 65.8% above its 52-week low of $373.00. The close sits above its 50-day moving average ($606.40) and above its 200-day moving average ($526.18).
NextPick tracks MEDP in its Life Sciences Tools basket alongside TMO, DHR, A, WAT and MTD. As of Oct 16, 2026, the basket's money-flow score is 7 (neutral), and the basket is up 1.2% over five sessions. Over the past month MEDP ranks 8th of 10 basket members by price change.
MEDP is scheduled to report earnings on Oct 21, 2026, after market close. Over its last 8 reports the stock moved an average of 16.8% on the first trading day after earnings, beating the options-implied move in 4 of 8.
MEDP options were pricing 55% at-the-money implied volatility on Oct 12, 2026, an IV rank of 54 over the past year.
Medpace is scheduled to report on Oct 21, 2026, after market close.
Over the last 8 reports, MEDP moved an average of 16.8% on the first trading day after earnings. The move beat the options-implied move in 4 of 8 reports.
Yes — the Oct 16, 2026 close of $618.47 is 17.5% above the 200-day average of $526.18.
MEDP closed 8.8% below its 52-week high of $677.90.
NextPick groups MEDP with TMO, DHR, A, WAT and MTD in its Life Sciences Tools basket.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
